Human models of low-grade inflammation: Bolus versus continuous infusion of endotoxin

Clinical and Vaccine Immunology

Volumn 14, Issue 3, 2007, Pages 250-255

  Taudorf, S ^a   Krabbe, K S ^a   Berg, R M G ^a   Pedersen, B K ^a   Moller K ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENDOTOXIN; HYDROCORTISONE; INTERLEUKIN 6; PLACEBO; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; MEAN ARTERIAL PRESSURE; NEUTROPHIL COUNT; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECTUM TEMPERATURE;

ADULT; BODY TEMPERATURE; CROSS-OVER STUDIES; ENDOTOXINS; HEART RATE; HUMANS; HYDROCORTISONE; INFLAMMATION; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-6; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; NEUTROPHILS; SINGLE-BLIND METHOD; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34147128114     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00380-06     Document Type: Article

References (25)

1. Bessey, P. Q., J. M. Watters, T. T. Aoki, and D. W. Wilmore. 1984. Combined hormonal infusion simulates the metabolic response to injury. Ann. Surg. 200:264-281.
2. Bethin, K. E., S. K. Vogt, and L. J. Muglia. 2000. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc. Natl. Acad. Sci. USA 97:9317-9322.
3. Duncan, B. B., M. I. Schmidt, J. S. Pankow, C. M. Ballantyne, D. Couper, A. Vigo, R. Hoogeveen, A. R. Folsom, and G. Heiss. 2003. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799-1805.
4. Elin, R. J., S. M. Wolff, K. P. McAdam, L. Chedid, F. Audibert, C. Bernard, and F. Oberling. 1981. Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J. Infect. Dis. 144:329-336.
5. Fijen, J. W., A. C. M. Kobold, P. de Boer, C. R. Jones, T. S. van der Werf, J. W. C. Tervaert, J. G. Zijlstra, and J. E. Tulleken. 2000. Leukocyte activation and cytokine production during experimental human endotoxemia. Eur. J. Intern. Med. 11:89-95.
6. Hansson, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352:1685-1695.
7. Reference deleted.
8. Krabbe, K. S., H. Bruunsgaard, J. Qvist, C. M. Hansen, K. Møller, L. Fonsmark, P. L. Madsen, G. Kronborg, U. Frandsen, H. O. Andersen, P. Skinhøj, and B. K. Pedersen. 2001. Hypotension during endotoxemia in aged humans. Eur. J. Anaesthesiol. 18:572-575.
9. Krabbe, K. S., A. Reichenberg, R. Yirmiya, A. Smed, B. K. Pedersen, and H. Bruunsgaard. 2005. Low-dose endotoxemia and human neuropsychological functions. Brain Behav. Immun. 19:453-460.
10. Krogh-Madsen, R., K. Møller, F. Dela, G. Kronborg, S. Jauffred, and B. K. Pedersen. 2004. Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-α, and FFAs to low-dose endotoxemia in humans. Am. J. Physiol. Endocrinol. Metab. 286:E766-E772.
11. Kumar, A., S. Zanotti, G. Bunnell, K. Habet, R. Anel, A. Neumann, M. Cheang, C. A. Dinarello, D. Cutler, and J. E. Parrillo. 2005. Interleukin-10 blunts the human inflammatory response to lipopolysaccharide without affecting the cardiovascular response. Crit. Care Med. 33:331-340.
12. Licastro, F., S. Pedrini, L. Caputo, G. Annoni, L. J. Davis, C. Ferri, V. Casadei, and L. M. Grimaldi. 2000. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 103:97-102.
13. Michie, H. R., K. R. Manogue, D. R. Spriggs, A. Revhaug, S. Odwyer, C. A. Dinarello, A. Cerami, S. M. Wolff, and D. W. Wilmore. 1988. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318:1481-1486.
14. Moller, D. E., and K. D. Kaufman. 2005. Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med. 56:45-62.
15. Mullington, J., C. Korth, D. M. Hermann, A. Orth, C. Galanos, F. Holsboer, and T. Pollmächer. 2000. Dose-dependent effects of endotoxin on human sleep. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278:R947-R955.
16. Petersen, A. M., and B. K. Pedersen. 2005. The anti-inflammatory effect of exercise. J. Appl. Physiol. 98:1154-1162.
17. Pollmächer, T., J. Mullington, C. Korth, W. Schreiber, D. Hermann, A. Orth, C. Galanos, and F. Holsboer. 1996. Diurnal variations in the human rest response to endotoxin. J. Infect. Dis. 174:1040-1045.
18. Reichenberg, A., R. Yirmiya, A. Schuld, T. Kraus, M. Haack, A. Morag, and T. Pollmächer. 2001. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58:445-452.
19. Santos, A. A., and D. W. Wilmore. 1996. The systemic inflammatory response: perspective of human endotoxemia. Shock 6:S50-S56.
20. Starkie, R., S. R. Ostrowski, S. Jauffred, M. Febbraio, and B. K. Pedersen. 2003. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-α production in humans. FASEB J. 17:884-886.
21. Steensberg, A., C. P. Fischer, C. Keller, K. Møller, and B. K. Pedersen. 2003. IL-6 enhances plasma IL-1ra, IL-10, and Cortisol in humans. Am. J. Physiol. Endocrinol. Metab. 285:E433-E437.
22. Turnbull, A. V., and C. L. Rivier. 1999. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol. Rev. 79:1-71.
23. van Enckevort, F. H., C. G. Sweep, P. N. Span, P. N. Demacker, C. C. Hennsen, and A. R. Hermus. 2001. Reduced adrenal response to bacterial lipopolysaccharide in interleukin-6-deficient mice. J. Endocrinol. Investig. 24:786-795.
24. Wellen, K. E., and G. S. Hotamisligil. 2005. Inflammation, stress, and diabetes. J. Clin. Investig. 115:1111-1119.
25. Yaffe, K., A. Kanaya, K. Lindquist, E. M. Simonsick, T. Harris, R. I. Shorr, F. A. Tylavsky, and A. B. Newman. 2004. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292:2237-2242.